1. Home
  2. NXDT vs CGEN Comparison

NXDT vs CGEN Comparison

Compare NXDT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NXDT

NexPoint Diversified Real Estate Trust

HOLD

Current Price

$4.88

Market Cap

259.1M

Sector

Finance

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$2.85

Market Cap

270.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXDT
CGEN
Founded
2012
1993
Country
United States
Israel
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
259.1M
270.4M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
NXDT
CGEN
Price
$4.88
$2.85
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$5.00
AVG Volume (30 Days)
125.2K
498.7K
Earning Date
01-01-0001
05-18-2026
Dividend Yield
9.66%
N/A
EPS Growth
N/A
N/A
EPS
0.99
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$75.09
P/E Ratio
$4.86
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.55
$1.30
52 Week High
$5.49
$3.24

Technical Indicators

Market Signals
Indicator
NXDT
CGEN
Relative Strength Index (RSI) 48.20 55.14
Support Level $3.37 $1.46
Resistance Level $4.96 $3.24
Average True Range (ATR) 0.29 0.16
MACD -0.05 -0.02
Stochastic Oscillator 35.39 63.73

Price Performance

Historical Comparison
NXDT
CGEN

About NXDT NexPoint Diversified Real Estate Trust

NexPoint Diversified Real Estate Trust is an externally advised REIT focused on the acquisition, asset management, development, and disposition of opportunistic, value-add investments in real estate properties throughout the United States. The company has two reportable segments: The Diversified reportable segment is focused on investing in various commercial real estate property types and across the capital structure, including but not limited to, equity, mortgage, debt, mezzanine debt and preferred equity. The Hospitality segment is focused on operating and renovating its U.S. located hospitality assets that meet its investment objective and criteria. Its Portfolio includes investments in the single-family rental, self-storage, office, hospitality, life science and multifamily sectors.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Share on Social Networks: